Some images has been designed using resources from Unsplash & Pixabay & Pexels & Freepik and some icons from Flaticon



  1. Kato K*, Cho BC, Takahashi M, Okada M, Lin CY, Chin K, Kadowaki S, Ahn MJ, Hamamoto Y, Doki Y, Yen CC, Kubota Y, Kim SB, Hsu CH, Holtved E, Xynos I, Kodani M, Kitagawa Y.  Nivolumab versus Chemotherapy in Patients with Advanced Oesophageal Squamous Cell Carcinoma Refractory or Intolerant to Previous Chemotherapy (ATTRACTION-3): A Multicentre, Randomised, Open-Label, Phase 3 Trial. Lancet Oncol 2019 Nov; 20(11): 1506-17. Epub 2019 Sep. (IF: 35.386; Oncology 3/229)

  2. Li CF, Chen JY, Ho YH, Hsu WH, Wu LC, Lan HY, Hsu DS, Tai SK, Chang YC*, Yang MH*.  Snail-Induced Claudin-11 Prompts Collective Migration for Tumour Progression. Nat Cell Biol 2019 Feb; 21(2): 251-62. Epub 2019 Jan. (IF: 19.064; Cell Biology 7/190)

  3. Yau T*, Hsu C, Kim TY, Choo SP, Kang YK, Hou MM, Numata K, Yeo W, Chopra A, Ikeda M, Kuromatsu R, Moriguchi M, Chao Y, Zhao H, Anderson J, Dela Cruz C, Kudo M.  Nivolumab in Advanced Hepatocellular Carcinoma: Sorafenib-Experienced Asian Cohort Analysis. J Hepatol 2019 Sep; 71(3): 543-52. Epub 2019 Jun. (IF: 18.946; Gastroenterology & Hepatology 3/84)

  4. Scagliotti G*, Moro-Sibilot D, Kollmeier J, Favaretto A, Cho EK, Grosch H, Kimmich M, Girard N, Tsai CM, Hsia TC, Brighenti M, Schumann C, Wang XA, Wijayawardana SR, Gruver AM, Wallin J, Mansouri K, Wacheck V, Chang GC.  A Randomized-Controlled Phase 2 Study of the MET Antibody Emibetuzumab in Combination with Erlotinib as First-line Treatment for EGFR-mutation Positive NSCLC Patients. J Thorac Oncol 2019 Oct. [Epub ahead of print] (IF: 12.460; Respiratory System 3/63; Oncology 10/230)

  5. Kelly RJ*, Lee J, Bang YJ, Almhanna K, Blum Murphy M, Catenacci DVT, Chung HC, Wainberg ZA, Gibson MK, Lee KW, Bendell JC, Denlinger CS, Chee CE, Omori T, Leidner R, Lenz HJ, Chao Y, Rebelatto MC, Brohawn P, He P, McDevitt J, Sheth S, Englert JM, Ku GY.  Safety and Efficacy of Durvalumab and Tremelimumab Alone or in Combination in Patients with Advanced Gastric and Gastroesophageal Junction Adenocarcinoma. Clin Cancer Res 2019 Nov. [Epub ahead of print] (IF: 8.911; Oncology 16/230)

  6. Cheng WC, Liao TT, Lin CC, Yuan LE, Lan HY, Lin HH, Teng HW, Chang HC, Lin CH, Yang CY, Huang SC, Jiang JK, Yang SH, Yang MH*, Hwang WL*.  RAB27B-Activated Secretion of Stem-like Tumor Exosomes Delivers the Biomarker microRNA-146a-5p, Which Promotes Tumorigenesis and Associates with an Immunosuppressive Tumor Microenvironment in Colorectal Cancer. Int J Cancer 2019 Oct; 145(8): 2209-24. Epub 2019 Apr. (IF: 7.360; Oncology 23/223)

  7. Hwang WL*, Lan HY, Cheng WC, Huang SC, Yang MH*.  Tumor Stem-Like Cell-Derived Exosomal RNAs Prime Neutrophils for Facilitating Tumorigenesis of Colon Cancer. J Hematol Oncol 2019 Jan; 12(1): 10. (IF: 7.333; Hematology 6/71; Oncology 24/223)

  8. Lai CH*, Tsai WS, Yang MH, Chou TY, Chang YC*.  A Two-Dimensional Immunomagnetic Nano-Net for the Efficient Isolation of Circulating Tumor Cells in Whole Blood. Nanoscale 2019 Nov; 11(44): 21119-27. Epub 2019 Sep. (IF: 6.970; Physics, Applied 18/148; Materials Science, Multidisciplinary 41/293; Chemistry, Multidisciplinary 26/172; Nanoscience & Nanotechnology 20/94)

  9. Ahn MJ*, Tsai CM, Shepherd FA, Bazhenova L, Sequist LV, Hida T, Yang JCH, Ramalingam SS, Mitsudomi T, Janne PA, Mann H, Cantarini M, Goss G.  Osimertinib in Patients with T790M Mutation-Positive, Advanced Non-Small Cell Lung Cancer: Long-Term Follow-Up from a Pooled Analysis of 2 Phase 2 Studies. Cancer 2019 Mar; 125(6): 892-901. Epub 2018 Dec. (IF: 6.537; Oncology 28/223)

  10. Chen YQ*, Kuo JC, Wei MT, Chen YC, Yang MH, Chiou A*.  Early Stage Mechanical Remodeling of Collagen Surrounding Head and Neck Squamous Cell Carcinoma Spheroids Correlates Strongly with Their Invasion Capability. Acta Biomater 2019 Jan; 84(): 280-92. Epub 2018 Nov. (IF: 6.383; Engineering, Biomedical 4/78; Materials Science, Biomaterials 3/33)

  11. Liu CY, Huang TT, Chen YT, Chen JL, Chu PY, Huang CT, Wang WL, Lau KY, Dai MS, Shiau CW, Tseng LM*.  Targeting SET to Restore PP2A Activity Disrupts an Oncogenic CIP2A-Feedforward Loop and Impairs Triple Negative Breast Cancer Progression. EBioMedicine 2019 Feb; 40(): 263-75. Epub 2019 Jan. (IF: 6.183; Medicine, Research & Experimental 13/133)

  12. Hsu JH, Chang PM, Cheng TS, Kuo YL, Wu AT, Tran TH, Yang YH, Chen JM, Tsai YC, Chu YS, Huang TH*, Huang CF*, Lai JM*.  Identification of Withaferin A as a Potential Candidate for Anti-Cancer Therapy in Non-Small Cell Lung Cancer. Cancers (Basel) 2019 Jul. [Epub ahead of print] (IF: 6.162; Oncology 31/229)

  13. Hung MH, Chen YL, Chen LJ, Chu PY, Hsieh FS, Tsai MH, Shih CT, Chao TI, Huang CY*, Chen KF*.  Canagliflozin Inhibits Growth of Hepatocellular Carcinoma via Blocking Glucose-Influx-Induced β-Catenin Activation. Cell Death Dis 2019 May; 10(6): 420. (IF: 5.959; Cell Biology 38/193)

  14. Lu LC, Hsu C, Shao YY, Chao Y, Yen CJ, Shih IL, Hung YP, Chang CJ, Shen YC, Guo JC, Liu TH, Hsu CH*, Cheng AL*.  Differential Organ-Specific Tumor Response to Immune Checkpoint Inhibitors in Hepatocellular Carcinoma. Liver Cancer 2019 Aug. [Epub ahead of print] (IF: 5.944; Oncology 35/229; Gastroenterology & Hepatology 14/84)

  15. Chang WM, Chang YC, Yang YC, Lin SK, Chang PM*, Hsiao M*.  AKR1C1 Controls Cisplatin-Resistance in Head and Neck Squamous Cell Carcinoma through Cross-Talk with the STAT1/3 Signaling Pathway. J Exp Clin Cancer Res 2019 Jun; 38(1): 245. (IF: 5.646; Oncology 40/229)

  16. Lee IC, Hung YW, Liu CA, Lee RC, Su CW, Huo TI, Li CP, Chao Y, Lin HC, Hou MC, Huang YH*.  A New ALBI-Based Model to Predict Survival after Transarterial Chemoembolization for BCLC Stage B Hepatocellular Carcinoma. Liver Int 2019 Sep; 39(9): 1704-12. Epub 2019 Jul. (IF: 5.542; Gastroenterology & Hepatology 16/84)

  17. Fang WL*, Chen MH, Huang KH, Chang SC, Lin CH, Chao Y, Lo SS, Li AF, Wu CW, Shyr YM.  Analysis of the Clinical Significance of DNA Methylation in Gastric Cancer Based on a Genome-Wide High-Resolution Array. Clin Epigenetics 2019 Nov; 11(1): 154. (IF: 5.496; Genetics & Heredity 21/174; Oncology 43/230)

  18. Moehler M*, Heo J, Lee HC, Tak WY, Chao Y, Paik SW, Yim HJ, Byun KS, Baron A, Ungerechts G, Jonker D, Ruo L, Cho M, Kaubisch A, Wege H, Merle P, Ebert O, Habersetzer F, Blanc JF, Rosmorduc O, Lencioni R, Patt R, Leen AM, Foerster F, Homerin M, Stojkowitz N, Lusky M, Limacher JM, Hennequi M, Gaspar N, McFadden B, De Silva N, Shen D, Pelusio A, Kirn DH, Breitbach CJ, Burke JM.  Vaccinia-Based Oncolytic Immunotherapy Pexastimogene Devacirepvec in Patients with Advanced Hepatocellular Carcinoma after Sorafenib Failure: A Randomized Multicenter Phase IIb Trial (TRAVERSE). Oncoimmunology 2019 Jun; 8(8): 1615817. (IF: 5.333; Immunology 31/158; Oncology 45/229)

  19. Yang YP, Nguyen PNN, Ma HI, Ho WJ, Chen YW, Chien Y, Yarmishyn AA, Huang PI, Lo WL, Wang CY, Liu YY, Lee YY, Lin CM, Chen MT, Wang ML*.  Tumor Mesenchymal Stromal Cells Regulate Cell Migration of Atypical Teratoid Rhabdoid Tumor through Exosome-Mediated miR155/SMARCA4 Pathway. Cancers (Basel) 2019 May. [Epub ahead of print] (IF: 5.326; Oncology 45/223)

  20. Liu CY*, Chu PY, Huang CT, Chen JL, Yang HP, Wang WL, Lau KY, Lee CH, Lan TY, Huang TT, Lin PH, Dai MS, Tseng LM.  Varlitinib Downregulates HER/ERK Signaling and Induces Apoptosis in Triple Negative Breast Cancer Cells. Cancers (Basel) 2019 Jan. [Epub ahead of print] (IF: 5.326; Oncology 45/223)

  21. Fang WL*, Huang KH, Chang SC, Lin CH, Chen MH, Chao Y, Lo SS, Li AF, Wu CW, Shyr YM.  Comparison of the Clinicopathological Characteristics and Genetic Alterations between Patients with Gastric Cancer with or without Helicobacter Pylori Infection. Oncologist 2019 Sep; 24(9): e845-53. Epub 2019 Feb. (IF: 5.306; Oncology 46/223)

  22. Chen MH*, Chang SC, Lin PC, Yang SH, Lin CC, Lan YT, Lin HH, Lin CH, Lai JI, Liang WY, Lu ML, Yang MH, Chao Y.  Combined Microsatellite Instability and Elevated Microsatellite Alterations at Selected Tetranucleotide Repeats (EMAST) Might Be a More Promising Immune Biomarker in Colorectal Cancer. Oncologist 2019 Jul. [Epub ahead of print] (IF: 5.252; Oncology 46/229)

  23. Leu CM, Hsu TS, Kuo YP, Lai MZ, Liu PC, Chen MH, Chang DM, Tsai CY, Chen MH*.  Deltex1 Suppresses T Cell Function and is a Biomarker for Diagnosis and Disease Activity of Systemic Lupus Erythematosus. Rheumatology (Oxford) 2019 Apr; 58(4): 719-28. (IF: 5.245; Rheumatology 5/30)

  24. Kao YC, Fang WL, Wang RF, Li AF, Yang MH, Wu CW, Shyr YM, Huang KH*.  Clinicopathological Differences in Signet Ring Cell Adenocarcinoma between Early and Advanced Gastric Cancer. Gastric Cancer 2019 Mar; 22(2): 255-63. Epub 2018 Aug. (IF: 5.045; Gastroenterology & Hepatology 13/80; Oncology 48/222)

  25. Satoh T, Kang YK, Chao Y, Ryu MH, Kato K, Cheol Chung H, Chen JS, Muro K, Ki Kang W, Yeh KH, Yoshikawa T, Oh SC, Bai LY, Tamura T, Lee KW, Hamamoto Y, Kim JG, Chin K, Oh DY, Minashi K, Cho JY, Tsuda M, Tanimoto M, Chen LT, Boku N*.  Exploratory Subgroup Analysis of Patients with Prior Trastuzumab Use in the ATTRACTION-2 Trial: a Randomized Phase III Clinical Trial Investigating the Efficacy and Safety of Nivolumab in Patients with Advanced Gastric/Gastroesophageal Junction Cancer. Gastric Cancer 2019 May. [Epub ahead of print] (IF: 5.045; Gastroenterology & Hepatology 13/80; Oncology 49/223)

  26. Ho WT, Chang JS, Chou SF, Hwang WL, Shih PJ, Chang SW, Yang MH, Jou TS*, Wang IJ*.  Targeting Non-Muscle Myosin II Promotes Corneal Endothelial Migration through Regulating Lamellipodial Dynamics. J Mol Med (Berl) 2019 Sep; 97(9): 1345-57. Epub 2019 Jul. (IF: 4.746; Genetics & Heredity 26/136; Medicine, Research & Experimental 29/174)

  27. Huang TH, Wu ATH, Cheng TS, Lin KT, Lai CJ, Hsieh HW, Chang PM, Wu CW, Huang CF*, Chen KY*.  In Silico Identification of Thiostrepton as an Inhibitor of Cancer Stem Cell Growth and an Enhancer for Chemotherapy in Non-Small-Cell Lung Cancer. J Cell Mol Med 2019 Dec; 23(12): 8184-95. Epub 2019 Oct. (IF: 4.658; Medicine, Research & Experimental 31/136; Cell Biology 60/193)

  28. Chung SY, Huang WC, Chen ZS, Chao TC, Su Y*.  Elucidation of the Mechanism Underlying CD44v6-Induced Transformation of IEC-6 Normal Intestinal Epithelial Cells. J Cell Physiol 2019 Jun; 235(1): 194-209. (IF: 4.522; Physiology 11/81; Cell Biology 64/193)

  29. Lai HT, Tseng WK, Huang SW, Chao TC, Su Y*.  MicroRNA-203 Diminishes the Stemness of Human Colon Cancer Cells by Suppressing GATA6 Expression. J Cell Physiol 2019 Sep. [Epub ahead of print] (IF: 4.522; Physiology 11/81; Cell Biology 64/193)

  30. Liu YM, Chan YL, Wu TH, Li TL, Hsia S, Chiu YH*, Wu CJ*.  Antitumor, Inhibition of Metastasis and Radiosensitizing Effects of Total Nutrition Formula on Lewis Tumor-Bearing Mice. Nutrients 2019 Aug. [Epub ahead of print] (IF: 4.171; Nutrition & Dietetics 16/86)

  31. Lee CC, Hsu SPC, Lin CJ, Wu HM, Chen YW, Luo YH, Chiang CL, Hu YS, Chung WY, Shiau CY, Guo WY, Hung-Chi Pan D, Yang HC*.  Epidermal Growth Factor Receptor Mutations: Association with Favorable Local Tumor Control Following Gamma Knife Radiosurgery in Patients with Non-Small Cell Lung Cancer and Brain Metastases. J Neurosurg 2019 Jun. [Epub ahead of print] (IF: 4.130; Surgery 18/203; Clinical Neurology 43/199)

  32. Lu HJ, Hsieh CC, Yeh CC, Yeh YC, Wu CC, Wang FS, Lai JM, Yang MH, Wang CH, Huang CF, Chang PM*.  Clinical, Pathophysiologic, and Genomic Analysis of the Outcomes of Primary Head and Neck Malignancy after Pulmonary Metastasectomy. Sci Rep 2019 Sep; 9(1): 12913. (IF: 4.011; Multidisciplinary Sciences 15/69)

  33. Peng SJ, Lee CC, Wu HM, Lin CJ, Shiau CY, Guo WY, Pan DH, Liu KD, Chung WY, Yang HC*.  Fully Automated Tissue Segmentation of the Prescription Isodose Region Delineated through the Gamma Knife Plan for Cerebral Arteriovenous Malformation (AVM) Using Fuzzy C-Means (FCM) Clustering. Neuroimage Clin 2019 -; 21(): 101608. Epub 2018 Nov. (IF: 3.869; Neuroimaging 3/14)

  34. Yeh CN*, Chen MH, Chang YC, Wu RC, Tsao LC, Wang SY, Cheng CT, Chiang KC, Chen TW, Hsiao M, Weng WH*.  Over-Expression of TNNI3K is Associated with Early-Stage Carcinogenesis of Cholangiocarcinoma. Mol Carcinog 2019 Feb; 58(2): 270-8. Epub 2018 Oct. (IF: 3.851; Biochemistry & Molecular Biology 83/293; Oncology 79/223)

  35. Liao CH, Lai IC, Kuo HC, Chuang SE, Lee HL, Whang-Peng J, Yao CJ*, Lai GM*.  Epigenetic Modification and Differentiation Induction of Malignant Glioma Cells by Oligo-Fucoidan. Mar Drugs 2019 Sep. [Epub ahead of print] (IF: 3.772; Chemistry, Medicinal 15/61)

  36. Chiang KC, Huang ST, Wu RC, Huang SC, Yeh TS, Chen MH, Hsu JT, Chen LW, Kuo SF, Chueh HY, Juang HH, Hung SI, Yeh CN*, Pang JS*.  Interferon α-Inducible Protein 27 is an Oncogene and Highly Expressed in Cholangiocarcinoma Patients with Poor Survival. Cancer Manag Res 2019 Feb; 11(): 1893-905. (IF: 3.702; Oncology 84/223)

  37. Wu CE, Chen MH, Yeh CN*.  mTOR Inhibitors in Advanced Biliary Tract Cancers. Int J Mol Sci 2019 Jan. [Epub ahead of print] (IF: 3.687; Chemistry, Multidisciplinary 52/171; Biochemistry & Molecular Biology 90/293)

  38. Chao TC, Pan WC, Tsai YF, Chou YC, Liu YR, Wang SF, Chen YJ, Sou?ek P, Ueng YF*.  Plasma Endoxifen and 4-Hydroxytamoxifen Levels in CYP2D6(C100T) Carrying Breast Cancer Patients and Association with Serum Cholesterol. Toxicol Appl Pharmacol 2019 Sep; 378(): 114619. Epub 2019 Jun. (IF: 3.585; Toxicology 21/93; Pharmacology & Pharmacy 67/267)

  39. Yen CC*, Chen SC, Hung GY, Wu PK, Chua WY, Lin YC, Yen CH, Chen YC, Wang JY, Yang MH, Chao Y, Chang MC, Chen WM.  Expression Profile?Driven Discovery of AURKA as a Treatment Target for Liposarcoma. Int J Oncol 2019 Oct; 55(4): 938-48. Epub 2019 Aug. (IF: 3.571; Oncology 86/229)

  40. Yen CC*, Chen LT, Li CF, Chen SC, Chua WY, Lin YC, Yen CH, Chen YC, Yang MH, Chao Y, Fletcher JA.  Identification of Phenothiazine as an ETV1?Targeting Agent in Gastrointestinal Stromal Tumors Using the Connectivity Map. Int J Oncol 2019 Aug; 55(2): 536-46. Epub 2019 Jun. (IF: 3.571; Oncology 86/229)

  41. Chang YJ, Ho CL, Cheng KH, Kuo WI, Lee WC, Lan KL, Chang CH*.  Biodistribution, Pharmacokinetics and Radioimmunotherapy of 188Re-Cetuximab in NCI-H292 Human Lung Tumor-Bearing Nude Mice. Invest New Drugs 2019 Oct; 37(5): 961-72. Epub 2019 Jan. (IF: 3.502; Pharmacology & Pharmacy 64/261; Oncology 92/223)

  42. Hung YP, Hu YW, Liu CJ*, Lin YJ, Chang SL, Lo LW, Hu YF, Tuan TC, Liao JN, Chung FP, Chen TJ, Chen SA, Albert CM, Chao TF*.  Risk and Predictors of Subsequent Cancers of Patients with Newly-Diagnosed Atrial Fibrillation - A Nationwide Population-Based Study. Int J Cardiol 2019 Dec; 296(): 81-6. Epub 2019 Aug. (IF: 3.471; Cardiac & Cardiovascular Systems 48/136)

  43. Ho HL, Chou TY, Yang SH, Jiang JK, Chen WS, Chao Y, Teng HW*.  PD-L1 is a Double-Edged Sword in Colorectal Cancer: the Prognostic Value of PD-L1 Depends on the Cell Type Expressing PD-L1. J Cancer Res Clin Oncol 2019 Jul; 145(7): 1785-94. Epub 2019 May. (IF: 3.282; Oncology 108/223)

  44. Tsai YF, Tseng LM, Lien PJ, Hsu CY*, Lin YS, King KL, Wang YL, Chao TC, Liu CY, Chiu JH, Yang MH.  HER2 Immunohistochemical Scores Provide Prognostic Information for Patients with HER2-Type Invasive Breast Cancer. Histopathology 2019 Mar; 74(4): 578-86. Epub 2019 Jan. (IF: 3.267; Pathology 18/79; Cell Biology 99/190)

  45. Kang YM, Chao TF, Wang TH*, Hu YW*.  Increased Risk of Pelvic Fracture after Radiotherapy in Rectal Cancer Survivors: A Propensity Matched Study. Cancer Med 2019 Jul; 8(8): 3639-47. Epub 2019 May. (IF: 3.202; Oncology 111/223)

  46. Chang SC, Lai YC, Chang CY, Huang LK, Chen SJ, Tan KT, Yu PN*, Lai JI*.  Concomitant Genetic Alterations are Associated with Worse Clinical Outcome in EGFR Mutant NSCLC Patients Treated with Tyrosine Kinase Inhibitors. Transl Oncol 2019 Nov; 12(11): 1425-31. Epub 2019 Aug. (IF: 3.138; Oncology 110/229)

  47. Chen JM, Yang TT, Cheng TS, Hsiao TF, Chang PM, Leu JY, Wang FS, Hsu SL, Huang CF, Lai JM*.  Modified Sijunzi Decoction can Alleviate Cisplatin-Induced Toxicity and Prolong the Survival Time of Cachectic Mice by Recovering Muscle Atrophy. J Ethnopharmacol 2019 Apr; 233(): 47-55. Epub 2018 Dec. (IF: 3.115; Integrative & Complementary Medicine 4/27; Plant Sciences 37/223; Chemistry, Medicinal 20/59; Pharmacology & Pharmacy 87/261)

  48. Lee CC*, Yang HC, Chen CJ, Lin CJ, Wu HM, Chung WY, Shiau CY, Guo WY, Pan DH.  Empirical Versus Progression-Guided Stereotactic Radiosurgery for Non-Functional Pituitary Macroadenomas after Subtotal Resection. J Neurooncol 2019 Apr; 142(2): 291-7. Epub 2019 Jan. (IF: 3.060; Clinical Neurology 78/197; Oncology 121/223)

  49. Hung YC, Lee CC, Guo WY, Shiau CY, Chang YC, Pan DH, Sheehan JP, Chung WY*.  Gamma Knife Radiosurgery for the Treatment of Cavernous Sinus Meningiomas: Post-Treatment Long-Term Clinical Outcomes, Complications, and Volume Changes. J Neurooncol 2019 Jun; 143(2): 261-70. Epub 2019 Apr. (IF: 3.060; Clinical Neurology 78/197; Oncology 121/223)

  50. Tai CC, Chen WS, Jiang JK, Yang SH, Wang HS, Chang SC, Lan YT, Lin CC, Lin HH, Huang SC, Cheng HH, Chao Y, Teng HW*.  Comparing Late-line Treatment Sequence of Regorafenib and Reduced-intensity FOLFOXIRI for Refractory Metastatic Colorectal Cancer. Am J Clin Oncol 2019 Nov. [Epub ahead of print] (IF: 3.015; Oncology 116/230)

  51. Chen JH, Huang WC, Bamodu OA*, Chang PM, Chao TY*, Huang TH*.  Monospecific Antibody Targeting of CDH11 Inhibits Epithelial-to-Mesenchymal Transition and Represses Cancer Stem Cell-Like Phenotype by Up-Regulating miR-335 in Metastatic Breast Cancer, in Vitro and in Vivo. BMC Cancer 2019 Jun; 19(1): 634. (IF: 2.933; Oncology 121/229)

  52. Hung GY, Horng JL, Chen PC, Lin LY, Chen JY, Chuang PH, Chao TC, Yen CC*.  Incidence of Soft Tissue Sarcoma in Taiwan: A Nationwide Population-Based Study (2007-2013). Cancer Epidemiol 2019 Jun; 60(): 185-92. Epub 2019 May. (IF: 2.888; Public, Environmental & Occupational Health 42/181; Oncology 129/223)

  53. Hsieh CH*, Tien HJ, Yu YB, Wu YH, Shueng PW, Lu YF, Wang SY, Wang LY*.  Simultaneous Integrated Boost with Helical Arc Radiotherapy of Total Skin (HEARTS) to Treat Cutaneous Manifestations of Advanced, Therapy-Refractory Cutaneous Lymphoma and Leukemia - Dosimetry Comparison of Different Regimens and Clinical Application. Radiat Oncol 2019 Jan; 14(1): 17. (IF: 2.862; Radiology, Nuclear Medicine & Medical Imaging 37/129; Oncology 132/223)

  54. Chang KB, Ye BW, Chou CK, Lee IC, Li CP, Chao Y, Huang YH, Hou MC, Lee KC*.  Outcomes of Enteral Metallic Stent in Patients with Pancreatic Carcinoma and Gastric Outlet Obstruction: A Single Center Experience. J Formos Med Assoc 2019 Jun. [Epub ahead of print] (IF: 2.844; Medicine, General & Internal 35/160)

  55. Teng HW*, Lin JK, Lin TC, Chen WS, Jiang JK, Yang SH, Wang HS, Chang SC, Lan YT, Lin CC, Lin HH, Huang SC.  Planned Short-Course Radiation (scRT) is Superior to Upfront Concurrent Chemoradiation (CCRT) in Treating Metastatic Rectal Cancer. J Gastrointest Surg 2019 May. [Epub ahead of print] (IF: 2.813; Surgery 48/200; Gastroenterology & Hepatology 47/80)

  56. Lee JC, Chuang KS, Hsueh Liu YW, Lin TY, Teng YC, Wang LW*.  A Comparison of Dose Distributions in Gross Tumor Volume between Boron Neutron Capture Therapy Alone and Combined Boron Neutron Capture Therapy Plus Intensity Modulation Radiation Therapy for Head and Neck Cancer. PLoS One 2019 Apr; 14(4): e0210626. (IF: 2.766; Multidisciplinary Sciences 15/64)

  57. Wang SJ, Huang WS, Chuang CM, Chang CH, Lee TW, Ting G, Chen MH, Chang PM, Chao TC, Teng HW, Chao Y, Chen YM, Lin TP, Chang YJ, Chen SJ, Huang YR, Lan KL*.  A Phase 0 Study of the Pharmacokinetics, Biodistribution, and Dosimetry of 188Re-Liposome in Patients with Metastatic Tumors. EJNMMI Res 2019 May; 9(1): 46. (IF: 2.630; Radiology, Nuclear Medicine & Medical Imaging 44/129)

  58. Young SH, Chau GY, Lee IC, Yeh YC, Chao Y, Huo TI, Su CW, Lin HC, Hou MC, Lee MH*, Huang YH*.  Aspirin is Associated with Low Recurrent Risk in Hepatitis B Virus-Related Hepatocellular Carcinoma Patients after Curative Resection. J Formos Med Assoc 2019 May. [Epub ahead of print] (IF: 2.452; Medicine, General & Internal 42/155)

  59. Chi CT, Chau GY, Lee RC, Chen YY, Lei HJ, Hou MC, Chao Y, Huang YH*.  Radiological Features and Outcomes of Combined Hepatocellular-Cholangiocarcinoma in Patients Undergoing Surgical Resection. J Formos Med Assoc 2019 Mar. [Epub ahead of print] (IF: 2.452; Medicine, General & Internal 42/155)

  60. Chen TH, Chang PM, Yang MH*.  Novel Immune-Modulating Drugs for Advanced Head and Neck Cancer. Head Neck 2019 Oct; 41 Suppl 1: 46-56. (IF: 2.442; Otorhinolaryngology 10/42; Surgery 66/203)

  61. Lee TL, Chiu PH, Li WY, Yang MH, Wei PY, Chu PY, Wang YF, Tai SK*.  Nerve-Tumor Interaction Enhances the Aggressiveness of Oral Squamous Cell Carcinoma. Clin Otolaryngol 2019 Oct. [Epub ahead of print] (IF: 2.377; Otorhinolaryngology 11/42)

  62. Xu ES, Yang MH, Huang SC, Liu CY, Yang TT, Chou TY*, Hwang TZ*, Hsu CT*.  ECE-1 Overexpression in Head and Neck Cancer is Associated with Poor Tumor Differentiation and Patient Outcome. Oral Dis 2019 Jan; 25(1): 44-53. Epub 2018 Oct. (IF: 2.310; Dentistry, Oral Surgery & Medicine 21/91)

  63. Hung YH, Lin YC, Lin YT, Shih GW, Liao JW, Chen KS, Liu HM, Chen YW, Chuang YJ, Yang CM, Peir JJ, Yang CH, Chou FI*.  Therapeutic Efficacy and Radiobiological Effects of Boric Acid-Mediated BNCT in a VX2 Multifocal Liver Tumor-Bearing Rabbit Model. Anticancer Res 2019 Oct; 39(10): 5495-504. (IF: 1.935; Oncology 185/230)

  64. Lee CC, Yang HC, Lin CJ, Chen CJ, Wu HM, Shiau CY, Guo WY, Hung-Chi Pan D, Liu KD, Chung WY, Peng SJ*.  Intervening Nidal Brain Parenchyma and Risk of Radiation-Induced Changes After Radiosurgery for Brain Arteriovenous Malformation: A Study Using an Unsupervised Machine Learning Algorithm. World Neurosurg 2019 May; 125(): e132-8. Epub 2019 Jan. (IF: 1.924; Surgery 95/200; Clinical Neurology 139/197)

  65. Chen PC*, Yen CC, Hung GY, Pan CC, Chen WM.  Gene Amplification and Tumor Grading in Parosteal Osteosarcoma. J Chin Med Assoc 2019 Oct. [Epub ahead of print] (IF: 1.894; Medicine, General & Internal 67/160)

  66. Chiu YH, Lai JI, Tseng CY, Wang SH, Li LH, Kao WF*, How CK, Chang WH, Hsieh CY.  Impact of Angiotension I Converting Enzyme Gene I/D Polymorphism on Running Performance, Lipid, and Biochemical Parameters in Ultra-Marathoners. Medicine (Baltimore) 2019 Jul; 98(29): e16476. (IF: 1.870; Medicine, General & Internal 69/160)

  67. Lee WP, Lan KL, Liao SX, Huang YH, Hou MC, Lan KH*.  Antiviral Effect of Saikosaponin B2 in Combination with Daclatasvir on NS5A Resistance-Associated Substitutions of Hepatitis C Virus. J Chin Med Assoc 2019 Mar; 82(5): 368-74. (IF: 1.660; Medicine, General & Internal 72/155)

  68. Chen JT, Lee HJ, Chen YW, Liang ML, Chen HH, Lee YY, Lirng JF, Luo CB, Chang FC*, Guo WY.  Prognostic Factors Related to Intratumoral Hemorrhage in Pediatric Intracranial Germ Cell Tumors. J Chin Med Assoc 2019 Feb; 82(2): 133-7. (IF: 1.660; Medicine, General & Internal 72/155)

  69. Yen HJ*, Yu TY, Lee CY, Hung GY, Chiou TJ, Chen HH, Lee YY, Liang ML, Chen YW.  The Impact on Outcomes by Using Thiotepa in Tandem Transplant for Pediatric High-Risk Embryonal Brain Tumors. J Chin Med Assoc 2019 Feb; 82(2): 148-54. (IF: 1.660; Medicine, General & Internal 72/155)

  70. Lin YC*, Chou FI, Yang BH, Chang CW, Chen YW, Hwang JJ.  Similar T/N Ratio between 18F-FBPA Diagnostic and BPA Therapeutic Dosages for Boron Neutron Capture Therapy in Orthotropic Tongue Cancer Model. Ann Nucl Med 2019 Oct. [Epub ahead of print] (IF: 1.648; Radiology, Nuclear Medicine & Medical Imaging 88/129)

  71. Yang WC, Yen HJ, Liang ML, Chen HH, Lee YY, Wong TT, Hu YW, Chen YW*.  Role of Early and Aggressive Post-Operative Radiation Therapy in Improving Outcome for Pediatric Central Nervous System Atypical Teratoid/Rhabdoid Tumor. Childs Nerv Syst 2019 Jun; 35(6): 1013-20. Epub 2019 Apr. (IF: 1.235; Pediatrics 86/124; Surgery 141/200; Clinical Neurology 172/197)

  72. Lin YJ, Hu YW, Twu NF, Liu YM*.  The Role of Adjuvant Radiotherapy in Stage I Endometrial Cancer: A Single-Institution Outcome. Taiwan J Obstet Gynecol 2019 Sep; 58(5): 604-9. (IF: 1.200; Obstetrics & Gynecology 70/83)

  73. Lin KH, Chen YW, Lee RC, Wang LW, Chou FI, Chang CW, Yen SH*, Huang WS*.  Nuclear Theranostics in Taiwan. Nucl Med Mol Imaging 2019 Apr; 53(2): 86-91. Epub 2019 Feb.